Phaseline

Targets › CRBN

CRBN (Protein cereblon): drug programs, companies and trials

18 programs from 10 companies in 252 trials: 139 Phase 2, 75 Phase 1, 37 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.

Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2, ILF2, GLUL, IKZF1 and CSNK1A1. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. (UniProt, Q96SW2)

Open in Phaseline: the race on CRBN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbCC-92480 (BMS-986348, mezigdomide)
Cereblon E3 ligase modulator (cereblon-binding protein that promotes IKZF1 and IKZF3 degra
CRBNPhase 3Relapsed or Refractory Multiple Myeloma; Multiple MyelomaNov 2026
National Cancer Institute (NCI)Thalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3DS Stage I Multiple Myeloma; Multiple MyelomaFeb 2027
IncyteLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed …Apr 2027
Bristol-Myers SquibbGolcadomide (CC-99282, BMS-986369)
Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader
CRBN, IKZF1, IKZF3Phase 3Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin …Apr 2027
Beijing InnoCare Pharma TechLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3DLBCLApr 2027
University of ArkansasThalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma; MyelomaAug 2027
Bristol-Myers SquibbIberdomide
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma …Nov 2027
Shandong New Time PharmaceuticalPomalidomide (F182112)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma …Dec 2027
Bristol-Myers SquibbMezigdomide
Cereblon E3 ubiquitin ligase modulator (CRBN modulator)
CRBNPhase 3Relapsed or Refractory Multiple MyelomaJul 2029
CellCentricPomalidomide (CCS1477)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma RefractoryNov 2029
RocheLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Follicular Lymphoma; Follicular LymphomaDec 2029
Fondazione Italiana Linfomi - ETSCC-99282 (Golcadomide)
Cereblon-binding IMiD (immunomodulatory imide drug) with anti-tumor and immunostimulatory
CRBNPhase 2Diffuse Large B Cell Non-Hodgkin LymphomaApr 2030
National Institute of Blood and Marrow Transplant (NIBMT), PakistanThalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 2Fetal Hemoglobin–
Bristol-Myers SquibbCC-122 (also: Avadomide, BMS-986381)
Cereblon E3 ligase modulator
CRBNPhase 1Non-Hodgkin LymphomaNov 2026
Bristol-Myers SquibbGolcadomide (BMS-986369, CC-99282)
Cereblon (CRBN) E3 ligase modulator
CRBNPhase 1Kidney Failure, Chronic; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed or Refractory T-cell LymphomasDec 2026
RocheIberdomide (CC-220)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple Myeloma; Non-Hodgkin LymphomaJul 2028
Bristol-Myers SquibbIberdomide (BMS-986382)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple MyelomaAug 2028
Bristol-Myers SquibbMezigdomide (BMS-986348, CC-92480)
Cereblon E3 ubiquitin ligase modulator
CRBNPhase 1Multiple Myeloma; Extramedullary Disease in Multiple Myeloma; KMT2A-rearranged; Relapsed Refractory Multiple Myeloma (RRMM) …Aug 2028

Conditions

Multiple Myeloma (59) Follicular Lymphoma (7) Plasma Cell Myeloma (7) Mantle Cell Lymphoma (6) DLBCL (5) Relapsed or Refractory Multiple Myeloma (5) Recurrent Multiple Myeloma (4) Diffuse Large B-cell Lymphoma (4) DS Stage I Multiple Myeloma (4) Multiple Myeloma in Relapse (4) Myeloma (3) Non-Hodgkin Lymphoma (3)

Modalities

mixed (11), small molecule (6), antibody (1)

Companies

Bristol-Myers Squibb (8) Roche (2) University of Arkansas (1) National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) Incyte (1) National Cancer Institute (NCI) (1) Shandong New Time Pharmaceutical (1) Beijing InnoCare Pharma Tech (1) Fondazione Italiana Linfomi - ETS (1) CellCentric (1)

Related targets

DDB1 (11) CUL4A (11) RBX1 (11) IKZF1 (1) IKZF3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.